NIMD

Company Overview

Snapshot

Founded in January 2015 by Anan Copty, PhD, NIMD operates with 1–10 employees. The company has raised $700,000 across one funding round. NIMD ceased operations in November 2018.

Business overview

NIMD (Noninvasive Medical Devices) is a medical device startup developing localized microwave thermal ablation devices for cancer treatment. Its core technology utilizes a noninvasive localized microwave heating applicator coupled with nanoparticles to selectively target cancer cells, aiming to deliver low microwave energy with high accuracy. The company's first product, Hyperthermed, is a compact medical device designed for use in hospitals and cancer clinics to treat specific cancer types, including breast cancer, with potential applications for skin melanomas, glioblastomas, and other head, neck, and lung cancers. NIMD operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers.

Company Intelligence Q&A

What is NIMD's primary focus in cancer treatment?

NIMD is primarily focused on developing noninvasive localized microwave thermal ablation devices for treating cancer, with an initial emphasis on breast cancer treatment.

What is Hyperthermed?

Hyperthermed is NIMD's first compact, versatile medical device designed for use in hospitals and cancer clinics to treat specific types of cancer using localized hyperthermia, selectively targeting cancer cells without damaging surrounding healthy tissue.

When was NIMD founded?

NIMD was founded in January 2015.

What is the status of NIMD's operations?

NIMD ceased to operate in November 2018.

Who are the founders of NIMD?

NIMD was founded by Anan Copty, PhD.